|

FDA-Approved Asundexian After Stroke: What 6.2% vs 8.4% Means

ByLife Choice Note

Bottom line: On November 9, 2026, the US FDA approved asundexian (Sunharbo) 50 mg, taken with antiplatelet therapy, for certain adults after a recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). In the pivotal trial, ischemic stroke occurred in 6.2% versus 8.4%. That result does not apply to every stroke survivor—and the drug is not approved for stroke prevention in atrial fibrillation.

Announcement: November 9, 2026 · Region: United States · Population: adults with a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA receiving antiplatelet therapy · Reviewed: November 11, 2026

What did the FDA approve?

Asundexian is a once-daily inhibitor of activated factor XI. The US indication is narrower than “stroke prevention”: it is used in combination with antiplatelet therapy after a recent non-cardioembolic ischemic stroke, with an NIH Stroke Scale score of 15 or less in the supporting trial, or after a high-risk TIA. A US approval does not automatically establish approval, coverage or the same indication in another country.

What does 6.2% vs 8.4% mean?

OCEANIC-STROKE was a phase 3, double-blind trial of 12,327 adults randomized within 72 hours of symptom onset. Everyone received planned single or dual antiplatelet therapy; participants received either asundexian 50 mg daily or placebo. Over a median follow-up of 19 months, ischemic stroke occurred in 6.2% and 8.4%, respectively (cause-specific hazard ratio 0.74; 95% CI, 0.65 to 0.84).

The simple absolute difference was 2.2 percentage points—about 22 fewer ischemic strokes per 1,000 trial participants over the study period. The FDA’s 26% figure is a relative reduction, not a 26-percentage-point reduction.

Did bleeding stay the same?

Major bleeding occurred in 1.9% with asundexian and 1.7% with placebo (hazard ratio 1.10; 95% CI, 0.85 to 1.44), so the overall difference was not statistically significant. This does not mean zero bleeding risk. The FDA reported more major bleeding among people older than 75 and during the first 90 days of treatment, while gastrointestinal bleeding was more common with asundexian. Diarrhea was the most frequent adverse reaction reported in at least 3% of treated participants.

Who was not established by this result?

  • People seeking stroke prevention for atrial fibrillation or another cardioembolic source
  • People with a severe index stroke beyond the trial’s NIHSS threshold
  • People starting treatment long after, rather than within days of, the qualifying event
  • Use without background antiplatelet therapy
  • People with moderate or severe hepatic impairment or important interacting medicines

The study is not a reason to stop, replace or add an antiplatelet or anticoagulant without individualized clinical review.

Important limitations

Bayer funded the trial. Median follow-up was about 19 months, so whether the net benefit persists for five or ten years is unknown. Eligibility required a recent event plus specified imaging or atherosclerotic features, limiting generalization to all TIA and stroke populations. The confidence interval around major bleeding also cannot exclude a clinically meaningful increase.

Primary sources

Prepared by: Life Choice Note, independent personal health-information explainer · Reviewed: November 11, 2026

This article explains official source material for general education. It is not a diagnosis or an instruction to start, stop or change treatment.

한국어로 읽기

Related guides